Advertisement

Neurotoxicity Research

, Volume 35, Issue 4, pp 883–897 | Cite as

Abundance of Synaptic Vesicle-Related Proteins in Alpha-Synuclein-Containing Protein Inclusions Suggests a Targeted Formation Mechanism

  • Amellia McCormack
  • Damien J. Keating
  • Nusha Chegeni
  • Alex Colella
  • Jing Jing Wang
  • Tim ChatawayEmail author
Original Article

Abstract

Proteinaceous α-synuclein-containing inclusions are found in affected brain regions in patients with Parkinson’s disease (PD), Dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). These appear in neurons as Lewy bodies in both PD and DLB and as glial cytoplasmic inclusions (GCIs) in oligodendrocytes in MSA. The role they play in the pathology of the diseases is unknown, and relatively little is still known about their composition. By purifying the inclusions from the surrounding tissue and comprehensively analysing their protein composition, vital clues to the formation mechanism and role in the disease process may be found. In this study, Lewy bodies were purified from postmortem brain tissue from DLB cases (n = 2) and GCIs were purified from MSA cases (n = 5) using a recently improved purification method, and the purified inclusions were analysed by mass spectrometry. Twenty-one percent of the proteins found consistently in the GCIs and LBs were synaptic-vesicle related. Identified proteins included those associated with exosomes (CD9), clathrin-mediated endocytosis (clathrin, AP-2 complex, dynamin), retrograde transport (dynein, dynactin, spectrin) and synaptic vesicle fusion (synaptosomal-associated protein 25, vesicle-associated membrane protein 2, syntaxin-1). This suggests that the misfolded or excess α-synuclein may be targeted to inclusions via vesicle-mediated transport, which also explains the presence of the neuronal protein α-synuclein within GCIs.

Keywords

Lewy body Glial cytoplasmic inclusion Parkinson’s disease Multiple system atrophy Vesicle trafficking Mass spectrometry 

Notes

Acknowledgements

We would like to acknowledge Dr. Weiping Gai for the anti-α-synuclein antibody, Ms. Fariba Chegini for her assistance with immunofluoresence and the South Australian Brain Bank for their support.

Funding

This study is financially supported by the Flinders Medical Centre Research Foundation, South Australia.

Supplementary material

12640_2019_14_MOESM1_ESM.doc (1 mb)
ESM 1 (DOC 1040 kb)

References

  1. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP (2008) Epidemiology of Parkinson's disease. J Neurol 255(Suppl 5):18–32CrossRefGoogle Scholar
  2. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38:515–517CrossRefGoogle Scholar
  3. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, Abbruzzese G, Tabaton M (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287:65–67CrossRefGoogle Scholar
  4. Burre J, Volknandt W (2007) The synaptic vesicle proteome. J Neurochem 101:1448–1462CrossRefGoogle Scholar
  5. Chen H, Chan DC (2009) Mitochondrial dynamics—fusion, fission, movement, and mitophagy—in neurodegenerative diseases. Hum Mol Genet 18:R169–R176CrossRefGoogle Scholar
  6. Cordato DJ, Chan DK (2004) Genetics and Parkinson’s disease. J Clin Neurosci 11:119–123CrossRefGoogle Scholar
  7. Culvenor JG, Rietze RL, Bartlett PF, Masters CL, Li QX (2002) Oligodendrocytes from neural stem cells express alpha-synuclein: increased numbers from presenilin 1 deficient mice. Neuroreport 13:1305–1308CrossRefGoogle Scholar
  8. Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14CrossRefGoogle Scholar
  9. Gai WP, Power JH, Blumbergs PC, Culvenor JG, Jensen PH (1999) Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J Neurochem 73:2093–2100Google Scholar
  10. Inoue M, Yagishita S, Ryo M, Hasegawa K, Amano N, Matsushita M (1997) The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems. Acta Neuropathol 93:585–591CrossRefGoogle Scholar
  11. Iwatsubo T, Yamaguchi H, Fujimuro M, Yokosawa H, Ihara Y, Trojanowski JQ, Lee VM (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol 148:1517–1529Google Scholar
  12. Jensen PH, Islam K, Kenney J, Nielsen MS, Power J, Gai WP (2000) Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments. J Biol Chem 275:21500–21507CrossRefGoogle Scholar
  13. Jin LT, Hwang SY, Yoo GS, Choi JK (2006) A mass spectrometry compatible silver staining method for protein incorporating a new silver sensitizer in sodium dodecyl sulfate-polyacrylamide electrophoresis gels. Proteomics 6:2334–2337CrossRefGoogle Scholar
  14. Keating DJ (2008) Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases. J Neurochem 104:298–305Google Scholar
  15. Klein C, Schlossmacher MG (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69:2093–2104CrossRefGoogle Scholar
  16. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38:518–520CrossRefGoogle Scholar
  17. Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, Jin J, Pan C, Shin J, Zhu D, Zhang J (2007) Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol 17:139–145CrossRefGoogle Scholar
  18. Licker V, Kovari E, Hochstrasser DF, Burkhard PR (2009) Proteomics in human Parkinson's disease research. J Proteome 73:10–29CrossRefGoogle Scholar
  19. Lindersson E, Lundvig D, Petersen C, Madsen P, Nyengaard JR, Højrup P, Moos T, Otzen D, Gai WP, Blumbergs PC, Jensen PH (2005) p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J Biol Chem 280:5703–5715CrossRefGoogle Scholar
  20. Link AJ, LaBaer J (2009) Proteomics: a Cold Spring Harbor laboratory course manual. Cold Spring Harbor laboratory press, Cold Spring HarborGoogle Scholar
  21. McCormack A, Chegeni N, Chegini F, Colella A, Power J, Keating D, Chataway T (2016) Purification of alpha-synuclein containing inclusions from human post mortem brain tissue. J Neurosci Methods 266:141–150CrossRefGoogle Scholar
  22. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien J, Playfer J, Reid W, International Psychogeriatric Association Expert Meeting on DLB (2004) Dementia with Lewy bodies. Lancet Neurol 3:19–28CrossRefGoogle Scholar
  23. Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB (2005) Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm 112:1613–1624CrossRefGoogle Scholar
  24. Onyango IG (2008) Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem Res 33:589–597CrossRefGoogle Scholar
  25. Ozawa T (2006) Pathology and genetics of multiple system atrophy: an approach to determining genetic susceptibility spectrum. Acta Neuropathol 112:531–538CrossRefGoogle Scholar
  26. Peiris H, Dubach D, Jessup CF, Unterweger P, Raghupathi R, Muyderman H, Zanin MP, Mackenzie K, Pritchard MA, Keating DJ (2014) RCAN1 regulates mitochondrial function and increases susceptibility to oxidative stress in mammalian cells. Oxidative Med Cell Longev 2014:520316CrossRefGoogle Scholar
  27. Pollanen MS, Bergeron C, Weyer L (1993) Deposition of detergent-resistant neurofilaments into Lewy body fibrils. Brain Res 603:121–124CrossRefGoogle Scholar
  28. Richter-Landsberg C, Gorath M, Trojanowski JQ, Lee VM (2000) Alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res 62:9–14CrossRefGoogle Scholar
  29. Shahmoradian SH, Genoud C, Graff-Meyer A, Hench J, Moors T, Schweighauser G, Wang J, Goldie KN, Suetterlin R, Castano-Diez D, Perez-Navarro P, Huisman E, Ipsen S, Ingrassia A, De Gier Y, Rozemuller AJ, Da Paepe A, Erny J, Staempfli A, Hoernschemeyer J, Grosserueschkamp F, Niedieker D, El-Mashtoly S, Quadri M, Van WF, Bonifati V, Gerwert K, Bohrmann B, Frank A, Britschgi M, Stahlberg H, Berg VD, Lauer ME (2017) Lewy pathology in Parkinson’s disease consists of a crowded organellar membranous medley. Cold Spring Harbor Laboratory Press, Cold Spring HarborGoogle Scholar
  30. Sian J, Hensiek R, Senitz D, Muench G, Jellinger K, Riederer P, Gerlach M (1998) A novel technique for the isolation of Lewy bodies in brain. Acta Neuropathol 96:111–115CrossRefGoogle Scholar
  31. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res 134:57–66CrossRefGoogle Scholar
  32. Tan EK (2007) The role of common genetic risk variants in Parkinson disease. Clin Genet 72:387–393CrossRefGoogle Scholar
  33. Uversky VN, Eliezer D (2009) Biophysics of Parkinson’s disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 10:483–499CrossRefGoogle Scholar
  34. Vanacore N (2005) Epidemiological evidence on multiple system atrophy. J Neural Transm 112:1605–1612CrossRefGoogle Scholar
  35. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, de Michele G, Marconi R, Nicholl D, Locuratolo N, Talarico G, Romano S, Stocchi F, Bonuccelli U, de Mari M, Vieregge P, Meco G, European Study Group on Atypical Parkinsonism (ESGAP) (2001) Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 22:97–99CrossRefGoogle Scholar
  36. Wakabayashi K, Takahashi H (2006) Cellular pathology in multiple system atrophy. Neuropathology 26:338–345CrossRefGoogle Scholar
  37. Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27:494–506CrossRefGoogle Scholar
  38. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12:133–147CrossRefGoogle Scholar
  39. Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG (2008) Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 64:239–246CrossRefGoogle Scholar
  40. Wilson CH, Zeile S, Chataway T, Nieuwenhuijs VB, Padbury RT, Barritt GJ (2011) Increased expression of peroxiredoxin 1 and identification of a novel lipid-metabolizing enzyme in the early phase of liver ischemia reperfusion injury. Proteomics 11:4385–4396CrossRefGoogle Scholar
  41. Wood-Kaczmar A, Gandhi S, Wood NW (2006) Understanding the molecular causes of Parkinson’s disease. Trends Mol Med 12:521–528CrossRefGoogle Scholar
  42. Yoshida M (2007) Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 27:484–493CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Flinders Proteomics Facility, College of Medicine and Public HealthFlinders UniversityBedford ParkAustralia
  2. 2.College of Medicine and Public HealthFlinders UniversityBedford ParkAustralia
  3. 3.Department of ImmunologyFlinders Medical Centre and Flinders University, SA PathologyBedford ParkAustralia

Personalised recommendations